Discovery and characterization of taspoglutide, a novel analogue of human glucagon‐like peptide‐1, engineered for sustained therapeutic activity in type 2 diabetes
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aim: Glucagon‐like peptide‐1 (GLP‐1) receptor agonists for the treatment of type 2 diabetes are administered by daily injection because of short plasma half‐lives, which result partly from the biochemical instability of these peptides. There is a medical need for GLP‐1 analogues that can be administered less frequently for patient convenience. Methods: We synthesized a series of human GLP‐1 (hGLP‐1(7‐36)NH 2 ) derivatives containing α ‐aminoisobutyric acid (Aib) substitutions, analysed their enzymatic stabilities and evaluated their secondary structures using circular dichroism (CD) and nuclear magnetic resonance (NMR). Results: Plasma stability experiments showed that only the analogue containing Aib substitutions in both the N‐terminus (position 8) and the C‐terminus (position 35), [Aib 8,35 ]hGLP‐1(7‐36)NH 2 (BIM‐51077), was fully resistant to enzymatic cleavage. Incubation with human plasma kallikrein or plasmin confirmed that the Aib substitution at position 35 prevented protease cleavage around this residue, which contributes to the significantly enhanced plasma stability and increased plasma half‐life. CD revealed increased C‐terminal α ‐helicity in Aib 35 ‐substituted analogues compared with both hGLP‐1(7‐36)NH 2 and analogues containing only Aib 8 substitutions. Based on NMR studies, the secondary structure of BIM‐51077 is similar to hGLP‐1(7‐36)NH 2 with a slight increase in α ‐helicity in the C‐terminus. Compared with hGLP‐1(7‐36)NH 2 , BIM‐51077 had similar binding affinity for the human GLP‐1 receptor and activated this receptor with similar potency. Conclusions: We have discovered an Aib 8,35 ‐substituted analogue of native hGLP‐1(7‐36)NH 2 (BIM‐51077) that retains the structure of the native peptide, and has similar activity and enhanced stability. A sustained‐release formulation of this molecule (taspoglutide) is in phase‐3 clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“GLP-1 is derived from differential posttranslational processing of proglucagon in L-cells and is secreted in two forms: a 31-mer peptide, GLP-1(7-37), and a C-terminally amidated 30-mer, GLP-1(7-36)NH2 [8].”
BackgroundEng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 1×
“Exendin-4 is a 39-mer peptide produced in the saliva of the Gila monster (Heloderma suspectum) [14], a lizard native to the southwestern United States and Mexico.”
BackgroundDeacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 7×
“E-mail: jesse.dong@ipsen.com In vivo, the amide bond linking Ala8 and Glu9 of native GLP-1 is rapidly cleaved by dipeptidylpeptidase-4 (DPP-4) [11], and the peptide has a plasma half-life of only approximately 2 min following intravenous administration [12] and 1 h after subcutaneous administration [13].”
BackgroundInfluentialThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Vilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges
Vinogradov, A. A., Yin, Y., & Suga, H. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b13178 · Cited by 848
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Impact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics
Ding, Y., Ting, J. P., Liu, J., Al-Azzam, S., Pandya, P., & Afshar, S. (2020) · Amino Acids · doi:10.1007/s00726-020-02890-9 · Cited by 200
Metadata
- Authors
- Dong, J. Z., Shen, Y., Zhang, J., Tsomaia, N., Mierke, D. F., & Taylor, J. E.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2010-11-28
- Volume
- 13
- Issue
- 1
- Pages
- 19-25
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W1966309593
- Cited by
- 38
- References
- 6
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery and characterization of taspoglutide, a novel analogue of human glucagon‐like peptide‐1, engineered for sustained therapeutic activity in type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1463-1326.2010.01313.x
- The paper
- Dong, J. Z., Shen, Y., Zhang, J., Tsomaia, N., Mierke, D. F., & Taylor, J. E. (2011). Discovery and characterization of taspoglutide, a novel analogue of human glucagon‐like peptide‐1, engineered for sustained therapeutic activity in type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2010.01313.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.